We have previously generated allogeneic gene-edited CAR-T targeting CD7 (UCART7) with biallelic deletion of CD7 and the T cell receptor alpha chain (TRAC), allowing for the generation of fratricide-resistant CAR-T targeting CD7+T cell malignancies without the risk of life-threatening GvHD [3]. Here, TRAC is linked to graft versus host disease.